New hope for kids with lupus: drug study shows promise
NCT ID NCT04179032
First seen Oct 31, 2025 · Last updated Jun 16, 2026 · Updated 31 times
Summary
This study tests a drug called belimumab, given as a shot under the skin, in children aged 5 to 17 with lupus. The goal is to find the right dose and check if it's safe when used with standard treatments. Lupus is a long-term disease where the immune system attacks the body, and this drug helps control that attack. The study involves 25 children and lasts about 68 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Cincinnati, Ohio, 45229, United States
-
GSK Investigational Site
Rosario, 2000, Argentina
-
GSK Investigational Site
Berlin, 13353, Germany
-
GSK Investigational Site
Saint Augustin, 53757, Germany
-
GSK Investigational Site
Kagoshima, 890-8520, Japan
-
GSK Investigational Site
Kanagawa, 216-8511, Japan
-
GSK Investigational Site
San Luis Potosí City, 78213, Mexico
-
GSK Investigational Site
Rotterdam, 3015 GJ, Netherlands
-
GSK Investigational Site
Barcelona, 08950, Spain
-
GSK Investigational Site
Madrid, 28034, Spain
-
GSK Investigational Site
Valencia, 46026, Spain
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.